Article: Novuspharma SpA Announces Results of BBR 2778 Study Show Potential in Chronic Model of Multiple Sclerosis.

Article: BBR 2778 Shows Promise In Preclinical Trials.(for the ...
Pain & Central Nervous System Week;  October 22, 2001 ;     700+ words ... ... the National Center for Multiple Sclerosis, together with colleagues ... results on the potential of BBR 2778 as a treatment for multiple sclerosis (MS) at the ECTRIMS conference in Dublin, Ireland. BBR 2778 is Novuspharma's ...

Article: Novuspharma SpA Announces Plans for Phase I Trial of Pixantrone ...
PR Newswire;  December 2, 2002 ;     700+ words ... ... trial of pixantrone (BBR 2778) in patients with multiple sclerosis (MS) in early 2003 ... Belgian National Centre for Multiple Sclerosis, on Saturday 30 November ... novuspharma.com/. Notes: Multiple Sclerosis Multiple sclerosis ...

Article: Novuspharma SpA results of BBR 2778 study show ...
Pain & Central Nervous System Week;  August 5, 2002 ;     700+ words ... ... preclinical study with BBR 2778 in a chronic model of multiple sclerosis. The results were presented ... examine the effect of BBR 2778 in a chronic, relapsing ... encephalomyelitis (EAE) model of multiple sclerosis by comparing BBR 2778 with mitoxantrone ...

Article: Novuspharma SpA results of BBR 2778 study show potential.
Drug Week;  August 9, 2002 ;     504 words ... ... preclinical study with BBR 2778 in a chronic model of multiple sclerosis. The results were presented ... examine the effect of BBR 2778 in a chronic, relapsing ... encephalomyelitis (EAE) model of multiple sclerosis by comparing BBR 2778 with mitoxantrone ...

Article: BBR 2778 Shows Promise In Preclinical Trials.
Drug Week;  November 2, 2001 ;     700+ words ... ... the National Center for Multiple Sclerosis, together with colleagues ... results on the potential of BBR 2778 as a treatment for multiple sclerosis (MS) at the ECTRIMS conference in Dublin, Ireland. BBR 2778 is Novuspharma's ...

Article: Plans announced for phase I trial of pixantrone (BBR 2778) ...
Biotech Week;  January 8, 2003 ;     525 words ... ... net) -- Novuspharma, SpA, (NOV.MI) announced plans to begin a phase I trial of pixantrone (BBR 2778) in patients with multiple sclerosis (MS) in early 2003. The trial is expected to recruit 15-20 patients in Europe. The main goal ...

Article: Does BBR render CGR and CGI DOA? Or, no matter what the ...
Directors & Boards;  March 22, 2008 ;     700+ words ... ... Bhagat, Brian Bolton, and Roberta Romano (BBR). Titled "The Promise and Peril of Corporate ... downloaded at www.ecgi.org/wp). BBR's principal points include: 1. Those ... indices and corporate performance. 2. BBR's analysis shows, on the contrary, that ...